Scott A Waldman

This inventor holds 43 USPTO granted patents and 17 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Cancer Therapeutics. Top assignee: Thomas Jefferson University. Active years: 1996-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Scott A Waldman. Retrieved from https://idiyas.com/inventor/scott-a-waldman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 43 (Patent Applications = 17)

% Patents Active = 58.1

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 10)

Average Co-Inventor Count = 1.7

ph-index = 14

Forward Citations = 868(Granted Patents)

Location History:

Ardmore, PA (US) (1996 - 2019)
Philadelphia, PA (US) (2022)

Company Filing History:

43 out of 538

Thomas Jefferson University

patents

Years Active: 1996-2026

Loading Chart...

Areas of Expertise:

Anti-Cancer Compositions

Colorectal Cancer

Chimeric Antigen Receptor

Guanlylylcyclase C

Cancer Cell Targeting

Metastatic Cancer Vaccine

ST Receptor Binding

CDX2 Expression

Diagnosis Kits

Pancreatic Cancer Detection

Tumor Marker Methods

Enterotoxigenic Diarrhea Treatment

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12758623 - ANTI-GUCY2C VACCINE COMPOSITIONS AND METHODS OF USING THEM (2026-10-13),

2. 11286308 - Cell based anti-cancer compositions with reduced toxicity and methods of making the same (2022-03-29),

3. 10202463 - Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same (2019-02-12),

4. 9662405 - Method of treating cancer by administering chimeric antigen receptor comprising anti-GCC antibody (2017-05-30),

5. 9447146 - Guanylylcyclase C ligands (2016-09-20),

6. 9429576 - Compositions and methods for identifying and targeting cancer cells of alimentary canal origin (2016-08-30),

7. 9393268 - Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same (2016-07-19),

8. 9156915 - Anti-GCC antibody molecules (2015-10-13),

9. 8946168 - Compositions and methods for identifying and targeting cancer cells of alimentary canal origin (2015-02-03),

10. 8563682 - Guanylylcyclase C ligands (2013-10-22),

11. 8329881 - Metastatic colorectal cancer vaccine (2012-12-11),

12. 8206704 - Use of GCC ligands (2012-06-26),

13. 8067007 - Compositions and methods for identifying and targeting cancer cells of alimentary canal origin (2011-11-29),

14. 7854933 - Compositions and methods for identifying and targeting cancer cells of alimentary canal origin (2010-12-21),

15. 7829276 - Methods of using CRCA-1 as a stomach and esophageal cancer marker (2010-11-09),

Title: The Innovative Journey of Scott A. Waldman

Introduction: Scott A. Waldman, a distinguished inventor hailing from Ardmore, PA (US), has made significant contributions to the field of innovations and patents.

Latest Patents: Scott A. Waldman holds several groundbreaking patents in the areas of biotechnology and medical devices, showcasing his commitment to advancing scientific research and healthcare technologies.

Career Highlights: Throughout his illustrious career, Scott A. Waldman has been recognized for his pioneering work in developing novel solutions for complex medical challenges. His innovative approach has led to the creation of cutting-edge technologies that have revolutionized the healthcare industry.

Collaborations: Scott A. Waldman has collaborated with leading researchers, scientists, and medical professionals to bring his inventions to life. His partnerships have been instrumental in driving forward progress in the field of biotechnology and medical innovation.

Conclusion: In conclusion, Scott A. Waldman's dedication to innovation and his passion for creating impactful solutions have solidified his reputation as a visionary inventor in the realm of biotechnology and medical devices. His contributions continue to inspire future generations of inventors and researchers.

Profile summary based on public USPTO records.